From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Canwell Biotech Ltd. has described antibody-drug conjugates (ADCs) comprising an antibody covalently linked to a Toll-like receptor 7 (TLR7) and TLR8 agonist through a cleavable or noncleavable linker ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

This makes ROR-1 an attractive therapeutic target for anti-cancer drug development. RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR-1, site specific conjugation to deliver a ...